Aviron Investment Management
Avenida Isidora Goyenechea 3000, Oficina 1702, Las Condes, Región Metropolitana de Santiago, 7550653, Chile
Overview
Aviron Investments is an independent asset management firm that specializes in investing across a variety of sectors including private equity, real estate, and public markets. With a focus on creating value for its investors, Aviron leverages its extensive track record and expertise to identify and capitalize on investment opportunities globally. The firm operates with a team of professionals dedicated to risk management and asset allocation, ensuring a strategic approach to investment. Aviron Investments is committed to delivering sustainable returns, employing a comprehensive analysis and due diligence process to guide its investment decisions.
- Total investments
- 3
- Lead investments
- 2
- Investments · 12mo
- 3
- Active investors
- 2
Sector focus
- Asset Management
- Financial Services
- Impact Investing
- Real Estate
- Real Estate Investment
Investment portfolio
- Ovum
Participated · Seed · Jun 2026
Ovum operates an AI-powered women’s health platform that captures both qualitative and quantitative health information to create longitudinal records of users’ clinical context. The company reports it has collected more than 60,000 health insights and facilitated over 113,000 AI health conversations, with users aged 15–84 tracking conditions from migraines and ADHD to PCOS, endometriosis and menopause. Ovum generates revenue through subscriptions and enterprise partnerships and has signed pilots and partnerships with organisations including Medibank, Fernwood Fitness, Sweat, Menopause Friendly Australia and Australian Red Cross Lifeblood. The startup has launched clinical trials with St George Hospital and the Royal Hospital for Women to assess AI as a preventative health tool for women. Ovum says 83% of its users have opted in to share anonymised data for research, and the company emphasises it will never sell user data and will only use data with explicit consent. Founded by Dr Ariella Heffernan-Marks in 2022, Ovum is positioning its dataset as a commercial research asset while stressing privacy, consent and clinical integrity.
- Lumonus
Led · Series B · Mar 2026
Founded in 2024, Lumonus offers an AI-native clinical care platform that streamlines end-to-end radiation oncology workflows. Its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, enable clinicians to consult and prescribe on cancer treatments more efficiently. The software is already deployed across the United States, Australia and Europe, where care teams have used it in more than 280,000 cancer treatment consultations and to automate over 75,000 treatment plans. With fresh funding, the company plans to expand its U.S. go-to-market and clinical success teams, bolster its clinical informatics capabilities, and further personalize its AI tools. Lumonus positions itself as a partner to oncology teams seeking data-driven, workflow-centric solutions. Financially, the startup has raised a total of $28 million in Series B financing, following a seed round backed by Oncology Ventures in March 2025.